Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells

British Journal of Pharmacology

Volumn 151, Issue 7, 2007, Pages 1041-1048

  Gkoumassi, E ^a   Dekkers, B G J ^a   Droge M J ^a   Elzinga, C R S ^a   Schmidt, M ^a   Meurs, H ^a   Zaagsma, J ^a   Nelemans, S A ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

cAMP; Cannabinoids; CP55,940; Human bronchial epithelium; Interleukin 8; Tumour necrosis factor ; Virodhamine

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CYCLIC AMP; INTERLEUKIN 8; MESSENGER RNA; PERTUSSIS TOXIN; PROTEIN; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA; VIRODHAMINE;

ARTICLE; BRONCHUS MUCOSA; CELL LINE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOASSAY; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

ADENYLATE CYCLASE; ANALGESICS; ARACHIDONIC ACIDS; BLOTTING, WESTERN; BORNANES; BRONCHI; CANNABINOIDS; CELL LINE; CYCLIC AMP; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; EPITHELIAL CELLS; FORSKOLIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-8; PERTUSSIS TOXIN; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547569055     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707320     Document Type: Article

References (28)

1. Barnes PJ, Chung KF, Page CP (1998). Inflammatory mediators of asthma: an update. Pharmacol Rev 50: 515-596.
2. Berdyshev EV (2000). Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 108: 169-190.
3. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998). Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287: 884-888.
4. Burkey TH, Quock RM, Consroe P, Ehlert FJ, Hosohata Y, Roeske WR et al. (1997). Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur J Pharmacol 336: 295-298.
5. Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K et al. (1994). CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 10: 38-47.
6. Demuth DG, Gkoumassi E, Dröge MJ, Dekkers BG, Esselink HJ, van Ree RM et al. (2005). Arachidonic acid mediates non-capacitative calcium entry evoked by CB(1)-cannabinoid receptor activation in DDT(1) MF-2 smooth muscle cells. J Cell Physiol 205: 58-67.
7. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48: 443-450.
8. i increases partly sensitive to capacitative store refilling. Eur J Pharmacol 336: R1-R3.
9. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
10. Glass M, Felder CC (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17: 5327-5333.
11. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
12. Ihenetu K, Molleman A, Parsons ME, Whelan CJ (2003). Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 458: 207-215.
13. Jan TR, Farraj AK, Harkema JR, Kaminski NE (2003). Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. Toxicol Appl Pharmacol 188: 24-35.
14. Jan TR, Kaminski NE (2001). Role of mitogen-activated protein kinases in the differential regulation of interleukin-2 by cannabinol. J Leukoc Biol 69: 841-849.
15. Klein TW (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400-411.
16. Linden A (1996). Increased interleukin-8 release by beta-adrenoceptor activation in human transformed bronchial epithelial cells. Br J Pharmacol 119: 402-406.
17. Mormina ME, Thakur S, Molleman A, Whelan CJ, Baydoun AR (2006). Cannabinoid signalling in TNF-alpha induced IL-8 release. Eur J Pharmacol 540: 183-190.
18. Nong L, Newton C, Cheng Q, Friedman H, Roth MD, Klein TW (2002). Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J Neuroimmunol 127: 169-176.
19. Oostendorp J, Postma DS, Volders H, Jongepier H, Kauffman HF, Boezen HM et al. (2005). Differential desensitization of homozygous haplotypes of the {beta}2-adrenergic receptor in lymphocytes. Am J Respir Crit Care Med 172: 322-328.
20. Pertwee RG (1999). Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6: 635-664.
21. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J et al. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301: 1020-1024.
22. Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H (2003). Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170: 4953-4962.
23. Sasaki K, Manabe H (2004). KF19514, a phosphodiesterase 4 and 1 inhibitor, inhibits TNF-alpha-induced GM-CSF production by a human bronchial epithelial cell line via inhibition of PDE4. Inflamm Res 53: 31-37.
24. Small-Howard AL, Shimoda LM, Adra CN, Turner H (2005). Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem J 388: 465-473.
25. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD (2002). Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42: 71S-81S.
26. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB(1) and CB(2) receptor agonists in vitro. Br J Pharmacol 150: 613-623.
27. Twitchell W, Brown S, Mackie K (1997). Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 78: 43-50.
28. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G et al. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398-1405.